NextCure and Simcere’s SIM0505 (CDH6 ADC) Phase 1 Data to be Presented at ASCO 2026
Rhea-AI Summary
NextCure (Nasdaq: NXTC) and Simcere will present Phase 1 data for SIM0505, an anti-CDH6 antibody-drug-conjugate (ADC), as a poster at ASCO 2026.
The poster (Abstract #5580, Board 246) will be presented June 1, 2026, by Xiaohua Wu, MD, PhD; the poster will be posted on the company investor site after the session.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – NXTC
On the day this news was published, NXTC declined 6.24%, reflecting a notable negative market reaction. Argus tracked a trough of -14.5% from its starting point during tracking. Our momentum scanner triggered 11 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $3M from the company's valuation, bringing the market cap to $44.58M at that time. Trading volume was elevated at 2.4x the daily average, suggesting increased selling activity.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
NXTC gained 13.32% while key biotech peers were mixed: BCTX down 9.26%, PRTG down 10.39%, and CARM sharply higher. With no peers in the momentum scanner, the move appears stock-specific to SIM0505’s ASCO Phase 1 update.
Previous Clinical trial Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Apr 07 | Fast Track designation | Positive | +0.9% | FDA granted Fast Track to SIM0505 in platinum-resistant ovarian cancer. |
| Nov 17 | PIPE financing | Positive | +2.7% | Closed $21.5M PIPE to fund ADC programs through key 2026 data readouts. |
| Oct 16 | Trial expansion | Positive | +27.8% | Expanded SIM0505 Phase 1 into U.S. with favorable mid-tier dose responses. |
| Jul 24 | Preclinical data | Positive | +17.3% | Promising NC605 OI preclinical data showing improved bone metrics in mice. |
| Jan 10 | First patient dosed | Positive | -6.1% | First patient dosed in LNCB74 Phase 1 trial for multiple cancers. |
Clinical and trial-related updates have often been followed by positive price reactions, with occasional sharp outliers both up and down.
Over the past year, NextCure has steadily advanced its antibody-drug conjugate pipeline. Key milestones include SIM0505’s Fast Track designation on Apr 7, 2026, a U.S. expansion of its Phase 1 trial on Oct 16, 2025, and first-patient dosing for LNCB74 in early 2025. Several clinical updates, including promising preclinical OI data, produced sizable single-day gains, while one LNCB74 milestone saw a decline. Today’s ASCO Phase 1 poster fits into this ongoing pattern of data-driven catalysts focused on SIM0505 and LNCB74.
Historical Comparison
In the past 5 clinical-trial updates, NXTC moved an average of 8.51%. Today’s 13.32% gain on the ASCO Phase 1 poster is moderately above that pattern.
Clinical-trial news has traced a progression from first-patient dosing and preclinical data, through U.S. expansion of the SIM0505 Phase 1 trial and Fast Track designation, to more mature Phase 1 data now highlighted at ASCO 2026.
Regulatory & Risk Context
An effective S-3 shelf filed on Nov 26, 2025 registers 2,523,477 shares for resale by selling stockholders, including shares underlying pre-funded warrants. NextCure does not receive proceeds from these resales beyond a limited amount upon warrant exercise, and no usage of this shelf is recorded to date.
Market Pulse Summary
The stock moved -6.2% in the session following this news. A negative reaction despite this ASCO-focused announcement would have contrasted with prior clinical catalysts, which averaged moves of 8.51% and often skewed positive. Investors have previously sold on certain milestones, such as LNCB74’s first-patient dosing, showing that not all data points are rewarded. Balance-sheet pressures and registered resale shares under the S-3 could also weigh on sentiment if enthusiasm for SIM0505 wavered.
Key Terms
antibody drug conjugate medical
adc medical
cadherin-6 medical
cdh6 medical
topoisomerase 1 inhibitor medical
first-in-human medical
fih medical
AI-generated analysis. Not financial advice.
Poster to be presented at the American Society for Clinical Oncology on Monday, June 1, 2026
BELTSVILLE, Md., April 21, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer and Simcere Zaiming Pharmaceutical Co., Ltd., (Simcere) an oncology-focused biopharmaceutical company and a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096), today announced a poster will be presented at ASCO 2026 highlighting Phase 1 data for SIM0505 in the treatment of solid tumors. ASCO 2026 is being held May 29 – June 2 in Chicago, Illinois. SIM0505 is an investigational antibody drug conjugate (ADC) targeting Cadherin-6 (CDH6) with a proprietary topoisomerase 1 inhibitor (TOPOi) payload.
“We are very pleased to announce that the Phase 1 results for SIM0505 have been accepted as a poster presentation at ASCO 2026. This important milestone validates our collaborative clinical approach and highlights our mission of advancing innovative medicines to treat cancer patients,” said Michael Richman, President and CEO of NextCure.
Presentation Details:
- Title: Phase 1, multicenter, first-in-human (FIH) global study of SIM0505, an anti-CDH6 (CDH6) antibody-drug-conjugate (ADC) in patients with advanced solid tumors
- Poster Abstract #: 5580
- Poster Board: 246
- Presenter: Xiaohua Wu, MD, PhD, Chief Physician and Chairman of the Multidisciplinary Team in Gynecologic Oncology at Fudan University Shanghai Cancer Center, Shanghai, China
- Session: Gynecologic Cancer
- Session Date: Monday June 1, 2026
- Session Time: 9:00 AM CST to 12:00 PM CDT
A full copy of the poster will be available on the NextCure website under the Investor Relations “Events & Presentations” tab following the presentation.
About SIM0505
SIM0505 is a novel antibody drug conjugate (ADC) directed to cadherin-6 (CDH6 ADC), featuring a proprietary topoisomerase 1 inhibitor (TOPOi) payload. The ADC is designed for broad anti-tumor activity, fast systemic clearance and an improved potential therapeutic window. SIM0505 is being evaluated in an open-label, Phase 1 study (NCT06792552) for the potential treatment of advanced solid tumors, including ovarian cancer, with an emphasis on platinum resistant ovarian cancer. NextCure holds exclusive global rights for SIM0505, excluding China, Hong Kong, Macau, and Taiwan which are retained by Simcere Zaiming Pharmaceutical Co., Ltd.
About NextCure, Inc.
NextCure is a clinical-stage biopharmaceutical company focused on advancing innovative medicines to treat cancer patients through the use of targeted therapies including antibody-drug conjugates. We focus on advancing therapies that leverage our core strengths in understanding biological pathways and biomarkers, the interactions of cells within and beyond the tumor microenvironment, and the role each interaction plays in a biologic response.
About Simcere Zaiming
Simcere Zaiming is an oncology-focused biopharmaceutical company and a subsidiary of Simcere Pharmaceutical Group Limited (HKEX: 2096, "Simcere"). Founded in 2023, Simcere Zaiming is dedicated to developing groundbreaking therapies to meet the unmet clinical needs of cancer patients globally. With a robust and innovative R&D pipeline featuring distinct clinical assets, Simcere Zaiming has successfully launched several innovative products in China, including Enzeshu®, COSELA®, Enweida®, Endostar®, and Enlituo®. The Company is determined to deliver potentially transformative treatment options to cancer patients worldwide through its internal R&D, manufacturing, and commercialization capabilities, complemented by strategic collaborations with leading partners.
Forward-Looking Statements
Some of the statements contained in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including with respect to funding for our operations, objectives and expectations for our business, operations and financial performance and condition, including the progress and results of clinical trials, development plans and upcoming milestones regarding our therapies. Any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “should”, “due”, “estimate”, “expect”, “intend”, “hope”, “may”, “objective”, “plan”, “predict”, “potential”, “positioned”, “seek”, “target”, “towards”, “forward”, “later”, “will”, “would”, and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or similar language.
Forward-looking statements involve substantial risks and uncertainties that could cause actual results to differ materially from those projected in any forward-looking statement. Such risks and uncertainties include, among others: market and other conditions; positive results in preclinical studies may not be predictive of the results of clinical trials; NextCure’s limited operating history and not having any products approved for commercial sale; NextCure’s history of significant losses; NextCure’s need and ability to obtain additional financing on acceptable terms or at all; risks related to clinical development, marketing approval and commercialization; NextCure’s reliance upon collaborators and international vendors for advancing clinical programs; NextCure’s ability to maintain listing of its common stock on the Nasdaq Global Select Market; and NextCure’s dependence on key personnel. More detailed information on these and additional factors that could affect NextCure’s actual results are described under the heading “Risk Factors” in NextCure’s most recent Annual Report on Form 10-K and in NextCure’s other filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. Forward-looking statements speak only as of the date of this press release, and NextCure assumes no obligation to update any forward-looking statements, even if expectations change.
Investor Inquiries
Timothy Mayer, Ph.D.
NextCure, Inc.
Chief Operating Officer
(240) 762-6486
IR@nextcure.com
Mike Moyer
Managing Director,
LifeSci Advisors, LLC
Phone: (617) 308-4306
mmoyer@lifesciadvisors.com
